Platelet component transfusion and alloimmunization: Where do we stand?

Area of Science:

• Onco-hematology
• Transfusion Medicine
• Immunology

Background:

• Platelet transfusions are frequently administered to patients, particularly those with onco-hematological conditions.
• Post-transfusion alloimmunization, a significant concern in multitransfused patients, arises from immune responses to platelet-specific (HPA) and HLA antigens.
• This immune response can lead to poor transfusion response, refractoriness, and rarely, post-transfusion purpura, compromising patient care.

Purpose of the Study:

• To highlight the challenges and implications of platelet alloimmunization in clinical practice.
• To emphasize the importance of compatible product selection in alloimmunized recipients.
• To underscore the role of technological advancements in managing transfusion outcomes.

Main Methods:

• Review of current understanding of platelet alloimmunization mechanisms.
• Discussion of antigen classes involved (HLA and HPA).
• Exploration of diagnostic and management strategies for alloimmunized patients.

Main Results:

• Platelet alloimmunization is a frequent complication, particularly in multitransfused onco-hematology patients.
• Alloimmunization leads to reduced transfusion effectiveness and potential adverse events like refractoriness and purpura.
• The presence of residual red blood cell antigens in platelet concentrates can also contribute to alloimmunization.

Conclusions:

• Effective management of platelet alloimmunization relies on the careful selection of compatible platelet products.
• Advancements in transfusion technologies offer improved methods for ensuring successful platelet transfusions.
• Optimizing transfusion strategies is essential for achieving satisfactory clinical outcomes in alloimmunized patients.